Revamped
AlloMune System Development Strategy: The company revised its clinical development strategy for the
AlloMune System and will now employ kits consisting of BioTransplant's proprietary antibody MEDI-507, also known as siplizumab, in combination with products that have already been approved in the United States.
In late July BioTransplant announced it was implementing a restructuring plan intended to streamline the company's operations around its most promising proprietary products-the
Allomune System and Eligix HDM Cell Separation technologies.
In the studies, miniature swine received a prototype of BioTransplant's
AlloMune System and a 30 to 60 day course of cyclosporin as conditioning for a high-dose peripheral blood stem cell (PBSC) transplant from haploidentical donors.
The Company's
AlloMune System is being developed to treat a variety of hematologic malignancies and solid organ transplants, and the Company has approval to market three of its Eligix HDM Cell Separation Systems in Europe.
BioTransplant says it is targeting the use of the Eligix Cell Separation products as a component of the
AlloMune System, which, along with its proprietary monoclonal antibody MEDI-507, is being developed as a complete approach to increase the safety and efficacy of immune modulation and transplantation for cancer and other life threatening diseases.
The
AlloMune System is designed to allow long-term organ acceptance without the use of chronic immunosuppressive drugs.
In addition, the Company is developing the
AlloMune System, which is designed to treat a variety of hematologic malignancies, and its distribution partner Gambro BCT markets the Eligix family of cell separation products in Europe for use in bone marrow, stem cell and donor leukocyte transplants.
In addition, the Company is developing the
AlloMune System, which is designed to treat a variety of hematologic malignancies, and its distribution partner, Gambro BCT, markets the Eligix family of cell separation products in Europe for use in bone marrow, stem cell and donor leukocyte transplants.
This news release contains forward-looking statements about BioTransplant that involve risks and uncertainties, including, without limitation, statements relating to the Company's expected revenues (including product revenue) for 2002, the implementation of the Company's restructuring plan, the Company's receipt of certain milestone payments, the ability of the Company to accelerate Eligix(TM) product sales, the ability of the Company to revise its clinical development strategy for its
AlloMune System, and the availability of cash.
We are implementing a multi-faceted restructuring initiative focused on BioTransplant's most promising proprietary products -- the
AlloMune System and Eligix HDM Cell Separation technologies," commented Donald B.
Recent data suggests that the
AlloMune System may help to reduce or eliminate the need for immunosuppressive therapy, and our collaborator, Massachusetts General Hospital, has just initiated an additional trial evaluating this treatment regimen in kidney transplant patients, in addition to ongoing trials in cancer patients.
AlloMune(TM) System BioTransplant is conducting Phase I/II clinical trials with the
AlloMune System, which will combine siplizumab with the HDM cell separation device to address the current problems of transplantation.
